Desmoid Tumors Breakthrough Treatment
Groundbreaking new drug, Ogsiveo, has been approved by the U.S. FDA as the first-ever systemic treatment for patients with desmoid tumors.
Groundbreaking new drug, Ogsiveo, has been approved by the U.S. FDA as the first-ever systemic treatment for patients with desmoid tumors.
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease…
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert…
Please join Rep. Quigley and the ALS Caucus Co-Chairs, Reps. Calvert, Crow, Fitzpatrick, and Sewell, for an event highlighting research and care for ALS. ALS…
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Ponni Subbiah, MD, MPH, Senior Vice President Global Head of Medical Affairs and Chief Medical Officer, Acadia Pharmaceuticals, discusses trofinetide for the treatment of Rett…
Dr. Varshavsky-Yanovsky discusses the safety of elranatamab in Black or African-American patients with multiple myeloma.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
The writers who craft ad copy have learned well from poets. But the words they wield have a different intent and power.
Madras motor neuron disease (MMND) is a rare childhood or juvenile motor neuron disease. Herein, we present a unique case of MMND in an 18-year-old…